Evidence map›Paper›PMID 29541946›Full record

ReviewCurrent psychiatry reports2018

Sex Differences in the Treatment of Sexual Dysfunction.

Veronica Harsh, Anita H Clayton

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current psychiatry reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Veronica HarshDepartment of Psychiatry & Neurobehavioral Sciences, University of Virginia, 2955 Ivy Rd, Suite 210, Charlottesville, VA, 22903, USA. vlh3p@hscmail.mcc.virginia.edu.
Anita H ClaytonDepartment of Psychiatry & Neurobehavioral Sciences, University of Virginia, 2955 Ivy Rd, Suite 210, Charlottesville, VA, 22903, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewSex differences in the treatment of sexual dysfunction are partly due to neurobiological differences, as well as, the central and peripheral physiological effects of hormones and neurotransmitter actions on reproductive systems in men and women. Differences in epidemiology of complaints and diagnostic considerations, variance in medical comorbidities, and interference from related medications also contribute to the need for different strategies for treatments of sexual dysfunction according to gender. RECENT

findingsFlibanserin and ospemifene are new medication treatment options that may help some women with symptoms of sexual dysfunction. Various therapies are available to address sexual dysfunction and sex differences are relevant to consider, in terms of diagnosis, effectiveness of treatments, and side effect profiles that may help determine indication, safety, and outcomes for specific treatments.

Indexed as

BenzimidazolesCognitive Behavioral TherapyFemaleHumansMalePhosphodiesterase 5 InhibitorsSelective Serotonin Reuptake InhibitorsSex FactorsSexual Dysfunction, PhysiologicalSexual Dysfunctions, PsychologicalTamoxifenTestosteroneBenzimidazolesflibanserinOspemifenePhosphodiesterase 5 InhibitorsSelective Serotonin Reuptake InhibitorsTamoxifenTestosteroneNeurobiologyPharmacotherapySex differencesSexual dysfunctionTreatment options

Identifiers

PMID29541946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.